Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05599620 · ClinicalTrials.gov registry record · NA
Reducing Alcohol Use and Sexual Dysfunction in Survivors of Sexual Trauma
A NA study of Sexual Dysfunction and Alcohol Use, Unspecified, sponsored by Lifespan.
- Active
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT05599620: Active NA study of Sexual Dysfunction and Alcohol Use, Unspecified, sponsored by Lifespan.
NCT05599620 is a NA study of Sexual Dysfunction and Alcohol Use, Unspecified that is active but no longer recruiting, run by Lifespan. The registered enrollment target is 90 participants, below the 963-participant average among 20 other Sexual Dysfunction trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05599620, a NA study of Sexual Dysfunction and Alcohol Use, Unspecified, is active but no longer recruiting, sponsored by Lifespan.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to develop and evaluate the preliminary efficacy of an intervention to address alcohol use, sexual distress, and sexual assault risk among college women with a history of sexual victimization. The main questions it aims to answer are: 1) what is the feasibility of the recruitment method, research design, interventionist training methods, and delivery of the intervention; 2) does the intervention, relatively to control, the 2- and 4-month follow-up produces reductions in the quantity/frequency of alcohol use and heavy drinking, sexual distress, and sex-related drinking motives, and sexual revictimization. Participants will engage in both individual and group based intervention for alcohol use, sexual distress, and sexual assault risk. Follow-up assessments are completed at 2- and 4-months following program completion. The intervention is compared to a wait list control group who will have the opportunity to complete the program after completing the 4-month follow up.
Primary Outcome
The number of past month drinking days (Minmum = 0, Maximum = 30), average drinks per drinking day (Minmum = 0, Maximum = unspecificed), number of heavy drinking days (Minimum = 0, Maximum = 30), assessed via the Time Line Follow Back, with greater scores meaning worse outcomes.
Conditions Studied
Interventions
- BEHAVIORAL AWARE
Study Locations (1)
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-02-14 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
What the registry record for NCT05599620 still lists
NCT05599620 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 963-participant average among 20 other Sexual Dysfunction trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Sexual Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which AWARE is the first listed.
NCT05599620 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT05599620 about?
NCT05599620 is a clinical study titled "Reducing Alcohol Use and Sexual Dysfunction in Survivors of Sexual Trauma". The goal of this clinical trial is to develop and evaluate the preliminary efficacy of an intervention to address alcohol use, sexual distress, and sexual assault risk among college women with a history of sexual victimization. The main questions it aims to answer are: 1) what is the feasibility of ...
What is the current status of trial NCT05599620?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2023-02-14. Estimated completion is 2026-04-30.
What conditions does trial NCT05599620 study?
This clinical trial studies the following conditions: Sexual Dysfunction, Alcohol Use, Unspecified, Sexual Assault.
What interventions are being tested in trial NCT05599620?
The interventions under investigation include: AWARE (BEHAVIORAL).
Who is sponsoring clinical trial NCT05599620?
This trial is sponsored by Lifespan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05599620 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sexual Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05599620's enrollment target sits among peer trials
90 9th of 20 higher than 12 of 20 other Sexual Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sexual Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
RECRUITING · NA
-
Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy
RECRUITING · NA
-
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women
RECRUITING · NA
-
Prostate Stimulation for Sexual Dysfunction
RECRUITING · NA
-
AYA OMGYES Sexual Health Study
RECRUITING · NA
-
Improving Women's Function After Pelvic Radiation
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI